Hongbo Lu

Hongbo Lu, Ph.D., is a Partner of Vivo Capital. Dr. Lu has close to 20 years of healthcare investment experience in both public securities and private companies. Prior to joining Vivo, she served as a Managing Partner at Lilly Asia Ventures (LAV). Prior to that, she served as a Managing Director at OrbiMed Advisors. She previously served on the boards of Turning Point Therapeutics, CrownBio, Avedro Inc., and Passage Bio and was extensively involved in the company incubations of ADARx Pharmaceuticals, Alpiscience, Geneception Therapeutics, Perfuse Therapeutics, Terns Pharmaceuticals, and Ronovo Pharmaceuticals since inception.

Dr. Lu earned a Ph.D. in Bioengineering from the University of Washington, an MBA. from the Haas School of Business at the University of California, Berkeley, and graduated with honors from Tsinghua University.